Search the Newsreel

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) reported Q2 earnings of $2.28 per share and revenues of $481 million, both exceeding Zacks Consensus Estimates. The company has consistently surpassed revenue estimates and its shares have outperformed the S&P 500 this year, though its Zacks Rank is currently "Hold" …

Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales

Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 47.7% year on year to $481 million. The company's full-year …

HALOZYME THERAPEUTICS ($HALO) Releases Q2 2026 Earnings, Stock Rises

Halozyme Therapeutics (NASDAQ: HALO) posts $481M Q2 2026 revenue

Halozyme Therapeutics (NASDAQ: HALO) reported total revenues of $481 million for Q2 2026 and $857.7 million for the first half of 2026, alongside a quarterly net income of $230 million. The biopharmaceutical company, which specializes in drug-delivery technologies like ENHANZE and Hypercon, saw significant …

Earnings Flash (HALO) Halozyme Therapeutics, Inc. Reports Q2 Revenue $481.0M, vs. FactSet Est of $402.3M

Halozyme Therapeutics, Inc. (HALO) reported robust Q2 revenue of $481.0 million, significantly exceeding FactSet's estimate of $402.3 million. The biopharmaceutical company also updated its 2026 adjusted EPS guidance to a range of $8.65-$9.00, surpassing the FactSet estimate of $7.94, and raised its 2026 revenue …

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Halozyme Therapeutics, Inc. reported record second-quarter 2026 financial results, exceeding estimates and subsequently raising its full-year 2026 financial guidance. The company saw a 48% year-over-year increase in total revenue to $481 million, with royalty revenue growing 50% to $308 million, driven by the strong …

Halozyme earnings up next: Can royalty growth hit $1B target?

Halozyme Therapeutics Inc. is reporting second-quarter earnings, with investors keenly watching its partnership momentum and progress toward a $1 billion ENHANZE royalty revenue target. The company has shown strong growth and secured multiple licensing deals, contributing to its stock trading near 52-week highs. Investors …

Halozyme Therapeutics, Inc. Revenue Breakdown – LSX:A0DLHS

Halozyme Therapeutics, Inc. generated 1.19 billion EUR in revenue last year, primarily from its Proprietary Enzymes, Devices, Hypercon Technology, and Surf Bio Technology segment. This revenue marks an increase from 980.78 million EUR in the previous year. The United States was the largest contributor, …

Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Expectations By $0.49 EPS

What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings

Halozyme Therapeutics (NASDAQ:HALO) is set to announce its Q2 earnings this Thursday. The company exceeded revenue expectations last quarter and analysts anticipate 24.1% year-on-year revenue growth for the upcoming report. Peers Biogen and Amgen have already reported strong Q2 results, with the therapeutics segment …

What Is the HALO Trade? Earnings, Not Assets, Will Decide the Next Winners

Halozyme Therapeutics Inc (HALO) - Tradingkey Stock Score & Comprehensive Stock Analysis

This article provides a comprehensive stock analysis of Halozyme Therapeutics Inc (HALO), highlighting its strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis notes significant institutional ownership and a "Buy" rating from analysts with an average target price of …

Is Halliburton (HAL) Undervalued On Earnings, Buybacks, And Its Australian AI Data Center MOU?

Halozyme Therapeutics Inc (HALO) Financial Health: Profitability & Balance Sheet Analysis

Halozyme Therapeutics Inc (HALO) currently holds a financial score of 8.39, placing it 51st out of 155 companies in the Pharmaceuticals industry. While its overall financial status is deemed weak, its operating efficiency is high. The company recently reported a 42.23% year-over-year increase in …

4% Undervalued? Halozyme Therapeutics (HALO) Nears Earnings At A Record High

Halozyme Therapeutics (HALO) has reached a record high ahead of its earnings release, with a 3-year shareholder return of 94.35%. While its valuation is considered 4.2% undervalued by some at $86.89 due to expanding partnerships and new product launches, its P/E ratio of 28.3x …

Is Halozyme Therapeutics (HALO) Fully Valued After Its 107% Gain?

Halozyme Therapeutics (HALO) has seen a significant 107.1% return over the past five years, but its current P/E ratio of 28.4x suggests it may be overvalued compared to its tailored fair P/E of 20.0x and the biotech industry average. While recent collaborations and the …

Precision Trading with Halozyme Therapeutics Inc. (HALO) Risk Zones

This article provides a detailed analysis of Halozyme Therapeutics Inc. (HALO) using AI models to identify potential trading strategies and risk zones. It highlights strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and …

Halozyme Therapeutics Inc (HALO) Institutional Confidence

Halozyme Therapeutics Inc (HALO) has a strong institutional confidence score of 10.00, ranking 1st in the Pharmaceuticals industry. The institutional shareholding proportion increased by 10.45% quarter-over-quarter to 117.14%. Bill Nygren from OAKMX is the largest institutional shareholder, holding 703.13K shares, a 186.36% increase in …

This Medical Technology Stock Claws Back To A Buy Zone

This medical technology name has a patented method of drug delivery. Halozyme stock recently hit a record high with earnings due out soon. Continue Reading

ETFs Investing in Halozyme Therapeutics, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Halozyme Therapeutics, Inc. The ETFs are sorted by their market value of Halozyme stocks and include details such as weight, issuer, management style, expense ratio, assets under management (AUM), price, change, and …

Gross margin % of Halo Minerals PLC – LSE:HALO

Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks

Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks As the craze of earnings season draws to a close, here's a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at …

Halo Minerals PLC Revenue Breakdown – LSE:HALO

Biotech Stocks At 52-Week Highs- IKT, HALO, JAZZ, CORT, LQDA

(RTTNews) - The following biotech stocks reached 52-week highs on July 24, 2026, driven by key catalysts like the upcoming release of quarterly reports or various regulatory milestones. Inhibikase Therapeutics Inc. (IKT) Inhikibase Therapeutics is a clinical-stage pharmaceutical company specializing in developing therapies for …

HALO|Halozyme Therapeutics Inc|Price:81.930|Chg%:+1.090

Halozyme Therapeutics Inc. (HALO) is a biopharmaceutical company focused on improving patient experiences through its ENHANZE drug delivery technology, which facilitates subcutaneous drug delivery. The company licenses this technology to partners and develops its own drug-device combination products like Hylenex and XYOSTED. The article …

Halozyme Therapeutics (HALO) Q4 2024 Earnings Report - Results, Call & Slides

Halozyme Therapeutics (HALO) has released its Q4 2024 earnings report, surpassing analyst expectations for both EPS and revenue. The company reported actual EPS of $22.06 against a consensus of $20.28, and actual revenue of $5.22 billion exceeding the expected $5.00 billion. The next earnings …

Halozyme Therapeutics Inc (HALO) Income Statement

This article presents the quarterly and annual income statements for Halozyme Therapeutics Inc (HALO), offering detailed financial insights into the company's performance, including revenue, expenses, and net income figures across various fiscal periods. It also provides an FAQ section explaining how to read the …

Halozyme Therapeutics, Inc. Revenue Breakdown – BX:RV7

This article provides a revenue breakdown for Halozyme Therapeutics, Inc. (BX:RV7), highlighting that the company generated 1.11 billion CHF last year, primarily from its Proprietary Enzymes, Devices, Hypercon Technology, and Surf Bio Technology segment. The United States was the largest contributor to this revenue, …

Halozyme Therapeutics Market Sentiment

This article provides an overview of Halozyme Therapeutics (HALO) market sentiment, including analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from analysts with a significant number of calls over puts, but also notes rising short interest and recent …

HALO5638653 Bond Risk Profile

This article provides a risk profile for the Halozyme Therapeutics, Inc. bond, HALO5638653, with a 1.0% coupon rate and maturity on August 15, 2028. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate …

HALO5638653 Bond Profile — Key Metrics

This article provides key metrics for the HALO5638653 bond issued by Halozyme Therapeutics, Inc. The bond has a 1.0% coupon rate and matures on August 15, 2028, with an outstanding amount of $470 million. Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company focused …

Halozyme Therapeutics stock hits all-time high at 82.42 USD

Halozyme Therapeutics Inc. (HALO) stock reached an all-time high of $82.42, reflecting a 37.55% growth over the past year. InvestingPro analysis suggests the stock is undervalued, indicating potential for further upside. Recent company developments include a collaboration with Incyte Pharmaceuticals and leadership changes, with …

Halozyme to host Aug. 6 call on second-quarter results

Halozyme (Nasdaq: HALO) announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, after the U.S. market close. The company will host a conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET …

HALO: Future Upside Will Rely On Expanding ENHANZE Drug Delivery Partnerships

Halozyme Therapeutics' fair value has been modestly increased to $86.89 per share due to updated assumptions around revenue growth and profitability, with analysts presenting mixed but focused views. Key developments include new partnerships with Incyte and GSK for its ENHANZE technology, positive clinical trial …

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Halozyme Therapeutics, Inc. (Nasdaq: HALO) will announce its second quarter 2026 financial and operating results on Thursday, August 6, 2026, after market close. The company will also host a conference call on the same day at 1:30 PM PT/4:30 PM ET to discuss these …

Halozyme Therapeutics to report Q2 2026 results on August 6

Halozyme Therapeutics announced that it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, after the close of trading. The company will host a conference call on the same day to discuss the results and provide stakeholders with …